Decision Benefits Medicaid Patients with Chronic Wounds

NEWPORT NEWS, Virginia (October 15, 2013) – Effective immediately, AHCCCS, the Arizona Medicaid Agency, will provide coverage for the use of TheraSkin®, a real skin therapy that effectively treats chronic wounds. This decision is consistent with the System’s primary Strategic Goal that AHCCCS “must pursue and implement long-term strategies that bend the cost curve while improving member health outcomes”.

“We applaud the decision by Arizona Medicaid to cover this limb and life-saving product,” said Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin, explaining that Arizona residents with diabetic and venous leg ulcers will now have access to cost-effective living cell therapy. Patients who have particularly benefited from the wound healing capabilities of TheraSkin are those with diabetes.

“Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.” TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.

The number of adults in Arizona with Type 2 diabetes has more than doubled in the last ten years; with an estimated 600,000 today. Cost to Arizona? About $3.3 billion per year. “We will work tirelessly with the medical institutions and practitioners in Arizona to help implement the clinical and economic benefits of TheraSkin,” said Allan Staley, president of Soluble Systems.

TheraSkin is not only clinically effective, but economical, costing 50 – 70% less than competing biologically active products, saving patients and payers thousands of dollars per treatment. A potent new weapon in the battle against rising healthcare costs, TheraSkin has the potential to save patients and the U.S. healthcare system more than $1 billion over the next decade.

TheraSkin is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing. Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing.

For more information on Arizona Medicaid coverage for TheraSkin, please visit: